Notably, we identified the TFE3 transcriptional target GPNMB as a cell surface biomarker that is upregulated in TFE3-fusion RCC, and evaluated a clinically relevant antibody-drug conjugate (ADC) that targets this protein in in vitro and in vivo assays. The gene discussed is TFE3; the disease is renal cell carcinoma.